Credit-Card Sized Device Wins FDA Clearance for At-Home Heart Monitoring

Sponsored:

Wednesday, December 10, 2025

Cardiac care is undergoing a fundamental shift as technology enables patients to capture critical health data outside traditional medical settings. The ability to record meaningful cardiac information during symptomatic episodes, rather than hours or days later in a doctor's office, represents a paradigm change in how physicians diagnose and manage heart conditions affecting millions of Americans.

Shares of HeartBeam, Inc. (NASDAQ: BEAT) are surging Wednesday after the company announced FDA 510(k) clearance for its groundbreaking 12-lead electrocardiogram (ECG) synthesis software for arrhythmia assessment. The clearance follows HeartBeam's successful appeal of a prior Not Substantially Equivalent (NSE) determination, marking a pivotal milestone in the company's commercialization strategy.

HeartBeam's patented technology represents the first cable-free device capable of synthesizing a 12-lead ECG from a credit-card sized device patients can use anywhere, anytime. Unlike single-lead or 6-lead consumer devices, HeartBeam captures the heart's electrical signals in three non-coplanar dimensions and synthesizes them into a 12-lead ECG representation. The synthesized reading is promptly reviewed by an on-demand, board-certified cardiologist, providing clinical-grade insights without requiring patients to visit a medical facility.

Dr. Robert A. Harrington, a world-renowned cardiologist and HeartBeam scientific advisory board member, emphasized the clinical significance, "One of the biggest challenges in cardiology is that cardiac symptoms most often don't happen in the doctor's office—they happen at home, at night, at work. The ability for patients to collect clinically meaningful ECG data at that exact moment, not hours later, can allow physicians to gain a much clearer understanding of a patient's condition."

The FDA clearance unlocks multiple growth initiatives for HeartBeam. The company plans a limited commercial launch in Q1 2026 targeting select concierge and preventive cardiology groups that have already signaled strong adoption interest. This approach will validate real-world performance and establish reference sites for broader commercialization.

Beyond arrhythmia monitoring, HeartBeam intends to pursue a heart attack detection indication supported by compelling proof-of-concept data, representing a major expansion into a market serving tens of millions of U.S. patients. The company is also advancing an on-demand 12-lead ECG extended wear patch, with a working prototype already developed for what management believes could be a best-in-class offering in an existing multi-billion-dollar reimbursed market.

CEO Robert Eno stated: "This FDA clearance is a defining moment for HeartBeam, and the true beginning of our mission to revolutionize cardiac care. We look forward to initiating our U.S. market introduction while advancing our efforts on heart attack detection, an on-demand 12-lead extended wear patch, and AI-based screening algorithms."

Shares of BEAT are up 58.9% to $1.28 in Wednesday morning trading.

Sponsored: